Skip to main content

Idamycin PFS Disease Interactions

There are 6 disease interactions with Idamycin PFS (idarubicin).

Major

Antineoplastics (applies to Idamycin PFS) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
  2. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
  3. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
  4. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
  5. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
  6. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
  8. "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
  9. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
  10. "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
  11. "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
  12. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
  14. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
  15. "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
  16. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
  17. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
  18. "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
  19. "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
  20. "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
  21. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
  22. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
  25. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
  27. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
  28. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
  29. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
View all 29 references
Major

Idarubicin (applies to Idamycin PFS) heart disease

Major Potential Hazard, Moderate plausibility.

Idarubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. Close clinical monitoring of cardiac function, such as an electrocardiogram and/or determination of left ventricular ejection fraction, prior to each course of therapy is recommended.

References

  1. Chan-Lam D, Copplestone JA, Prentice A, Price R, Johnson S, Phillips M "Idarubicin cardiotoxicity in acute myeloid leukaemia." Lancet 340 (1992): 185-6
  2. Bertelli G, Amoroso D, Pronzato P, Rosso R "Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors." Anticancer Res 8 (1988): 645-6
  3. Villani F, Galimberti M, Comazzi R, Crippa F "Evaluation of cardiac toxicity of idarubicin (4- demethoxydaunorubicin)." Eur J Cancer Clin Oncol 25 (1989): 13-8
  4. Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S "Phase II trial of idarubicin in patients with advanced lymphoma." Cancer Chemother Pharmacol 21 (1988): 261-4
  5. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
View all 5 references
Major

Idarubicin (applies to Idamycin PFS) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Idarubicin undergoes extensive extrahepatic metabolism and is primarily eliminated by biliary excretion. The pharmacokinetic disposition of idarubicin has not been studied in leukemia patients with hepatic impairment. It is thought that the metabolism of idarubicin would be decreased in moderate to severe hepatic dysfunction and lead to increased systemic drug levels and toxicity. Therapy with idarubicin should be administered cautiously and dosage reduction considered in patients with compromised hepatic function. Idarubicin injection should not be administered if bilirubin level exceeds 5 mg %. Clinical monitoring of hepatic function is recommended prior to and during therapy.

References

  1. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al. "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
  2. Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
  3. Lowenthal RM, Chesterman CN, Griffiths JD, Manoharan A, Harris MG, Herrmann RP, Rooney KF, Rozenberg MC, Salem HH, Wolf MM, et al. "Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients." Cancer Treat Rep 71 (1987): 1279-81
  4. Chisesi T, Capnist G, de Dominicis E, Dini E "A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma." Eur J Cancer Clin Oncol 24 (1988): 681-4
  5. Dodion P, Finet C, Crespeigne N, Beer M, Nicaise C, Rozencweig M, Kenis Y "Phase I study of oral idarubicin given with a weekly schedule." Invest New Drugs 4 (1986): 31-8
  6. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
  7. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
View all 7 references
Major

Idarubicin (applies to Idamycin PFS) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Bleeding, Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Idarubicin induces severe myelosuppression at therapeutic doses. Therapy with idarubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. If the need outweighs the risk, extreme caution should be exercised in administering idarubicin. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

References

  1. Elbaek K, Ebbehoj E, Jakobsen A, Juul P, Rasmussen SN, Bastholt L, Dalmark M, Steiness E, Ebbehj E "Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects." Clin Pharmacol Ther 45 (1989): 627-34
  2. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al. "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
  3. Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
  4. Case DC Jr, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS, Pruitt BT, Gould J "Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma." Cancer Res 52 (1992): 3871-4
  5. Chevallier B, Monnier A, Metz R, Namer M, Marty M, Roche H, Bastit P, Hurteloup P "Phase II study of oral idarubicin in elderly patients with advanced breast cancer." Am J Clin Oncol 13 (1990): 436-9
  6. van Eys J, Steuber P, Haggard ME, Sabio H, Duncan M "Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study." Am J Pediatr Hematol Oncol 3 (1981): 301-3
  7. Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S "Phase II trial of idarubicin in patients with advanced lymphoma." Cancer Chemother Pharmacol 21 (1988): 261-4
  8. Milroy R, Cummings J, Kaye SB, Banham SW "Phase II clinical and pharmacological study of oral 4- demethoxydaunorubicin in advanced non-pretreated small cell lung cancer." Cancer Chemother Pharmacol 20 (1987): 75-7
  9. Ganzina F, Pacciarini MA, Di Pietro N "Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies." Invest New Drugs 4 (1986): 85-105
  10. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
  11. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
View all 11 references
Major

Idarubicin (applies to Idamycin PFS) renal dysfunction

Major Potential Hazard, Moderate plausibility.

Impaired renal function can affect the disposition of idarubicin. Therapy with idarubicin should be administered cautiously and dosage modification considered in patients with compromised renal function. Clinical monitoring of renal function is recommended prior to and during therapy.

References

  1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
Moderate

Idarubicin (applies to Idamycin PFS) hyperuricemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperuricemia Secondary to Chemotherapy

Treatment with idarubicin may cause hyperuricemia as a result of rapid lysis of tumor cells. Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.

References

  1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):

Idamycin PFS drug interactions

There are 500 drug interactions with Idamycin PFS (idarubicin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer